This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy Policy.
Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in AGA Alopecia
MORE
Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer
Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation
Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development
Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor
Follow Us
Top